Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes

被引:1
|
作者
Medina, Miguel [1 ]
Avila, Jesus [1 ,2 ]
机构
[1] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid 28041, Spain
[2] Ctr Biol Mol Severo Ochoa CSIC UAM, Madrid 28049, Spain
关键词
Alzheimer's; dementia; GSK-3; long-term depression; long-term potentiation; memory; neurodegeneration; synaptic plasticity; GLYCOGEN-SYNTHASE KINASE-3; BETA PRECURSOR PROTEIN; LONG-TERM POTENTIATION; TAU-PROTEIN; IN-VIVO; TRANSGENIC MICE; AMYLOID PATHOLOGY; NEURONAL POLARITY; SIGNALING PATHWAY; EXTRACELLULAR TAU;
D O I
10.1586/ERN.13.39
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Originally discovered because of its role in the regulation of glucose metabolism, GSK-3 is now widely recognized as a crucial player in many cellular functions. Control of GSK-3 activity occurs by complex mechanisms that are each dependent upon specific signaling pathways. Furthermore, GSK-3 dysfunction has been linked to a number of pathologies, including Alzheimer's disease (AD). In particular, the involvement of GSK-3 in several key pathophysiological pathways leading to AD and neurodegenerative diseases has placed this enzyme in a central position in this disorder. In this article, the authors will specifically focus on the role of this enzyme as a key regulator of synaptic plasticity and how alterations in the GSK-3 synaptic functions may be a major factor in AD and other neurodegenerative disorders.
引用
收藏
页码:495 / 503
页数:9
相关论文
共 50 条
  • [21] GSK-3 inhibitors: A New Class of Drugs for Alzheimer's Disease Treatment
    Pal, Dilipkumar
    Mukherjee, Souvik
    Song, In-Ho
    Nimse, Satish B.
    CURRENT DRUG TARGETS, 2021, 22 (15) : 1725 - 1737
  • [22] GSK-3α regulates production of Alzheimer's disease amyloid-β peptides
    Christopher J. Phiel
    Christina A. Wilson
    Virginia M.-Y. Lee
    Peter S. Klein
    Nature, 2003, 423 : 435 - 439
  • [23] Treatment of Alzheimer's Disease with the GSK-3 Inhibitor Tideglusib: A Pilot Study
    del Ser, Teodoro
    Steinwachs, Klaus C.
    Gertz, Hermann J.
    Andres, Maria V.
    Gomez-Carrillo, Belen
    Medina, Miguel
    Vericat, Joan A.
    Redondo, Pilar
    Fleet, David
    Leon, Teresa
    JOURNAL OF ALZHEIMERS DISEASE, 2013, 33 (01) : 205 - 215
  • [24] GSK-3 inhibitors: preclinical and clinical focus on CNS
    Eldar-Finkelman, Hagit
    Martinez, Ana
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2011, 4
  • [25] Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimer's Disease
    Medina, Miguel
    Avila, Jesus
    CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (25) : 2790 - 2798
  • [26] TDZD:: Selective GSK-3 inhibitors with great potential for Alzheimer disease
    Martínex, A
    NEUROBIOLOGY OF AGING, 2006, 27 : S13 - S13
  • [27] GSK-3β modulates AMPA receptor internalization and synaptic plasticity:: Relevance for mood disorders
    Wang, Yun
    Du, Jing
    Wei, Yanling
    Machado-Vieira, Rodrigo
    Malkesman, Oz
    Chen, Guang
    Manji, Husseini K.
    BIOLOGICAL PSYCHIATRY, 2008, 63 (07) : 62S - 62S
  • [28] GSK-3β deletion in dentate gyrus excitatory neuron impairs synaptic plasticity and memory
    Enjie Liu
    Ao-Ji Xie
    Qiuzhi Zhou
    Mengzhu Li
    Shujuan Zhang
    Shihong Li
    Weijin Wang
    Xiaochuan Wang
    Qun Wang
    Jian-Zhi Wang
    Scientific Reports, 7
  • [29] GSK-3β deletion in dentate gyrus excitatory neuron impairs synaptic plasticity and memory
    Liu, Enjie
    Xie, Ao-Ji
    Zhou, Qiuzhi
    Li, Mengzhu
    Zhang, Shujuan
    Li, Shihong
    Wang, Weijin
    Wang, Xiaochuan
    Wang, Qun
    Wang, Jian-Zhi
    SCIENTIFIC REPORTS, 2017, 7
  • [30] GSK-3β dysregulation in aging: Implications for tau pathology and Alzheimer's disease progression
    Rekha, A.
    Afzal, Muhammad
    Babu, M. Arockia
    Menon, Soumya, V
    Nathiya, Deepak
    Supriya, S.
    Mishra, Shakti Bedanta
    Gupta, Sofia
    Goyal, Kavita
    Rana, Mohit
    Ali, Haider
    Imran, Mohd
    MOLECULAR AND CELLULAR NEUROSCIENCE, 2025, 133